Drug Database
Back to search

Netherlands· NL-157a8be7dd22

Vimizim 1 mg/ml concentraat voor oplossing voor infusie

A elosulfase alfa product containing elosulfase alfa, registered in Netherlands by BioMarin International Limited. The same ATC class is registered in 14 of our 19 countries.

ATC A16AB12

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedVimizim 1 mg/ml concentraat voor oplo…ATCA16AB12REGISTER NO.NL-157a8be7dd22PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about elosulfase alfaAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Elosulfase alfa is registered in 14 of 19 countries.

Countries holding a registration under ATC A16AB12 (elosulfase alfa), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose
Search elosulfase alfa products by name

Elosulfase alfa · ATC A16AB12

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
ELOSULFASE ALFA
Manufacturer
BioMarin International Limited
Country
Netherlands (NL)
ATC code
A16AB12
ATC class
Elosulfase alfa
Defined daily dose
20 mg, P
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/14/914

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Elosulfase alfa in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All elosulfase alfa products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Vimizim
  • Liechtenstein · Vimizim
  • Norway · Vimizim

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/aaa754ba-cec7-453f-928f-8559e296c0c5
GET /v1/drugs/aaa754ba-cec7-453f-928f-8559e296c0c5?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Concentraat voor oplossing voor infusie",
  "route": "Intraveneus gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/vimizim-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Elosulfase alfa",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp113712",
  "excipients": [
    "ARGININEHYDROCHLORIDE, (L-)",
    "NATRIUMACETAAT 3-WATER (E 262)",
    "NATRIUMDIWATERSTOFFOSFAAT 1-WATER (E 339)",
    "POLYSORBAAT 20 (E 432)",
    "SORBITOL (E 420)",
    "WATER VOOR INJECTIE"
  ],
  "substances": [
    "ELOSULFASE ALFA"
  ],
  "leaflet_url": null,
  "authorised_at": "2014/04/28",
  "procedure_number": "EMEA/H/C/002779",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/14/914",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about elosulfase alfa.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console